Analysts expect that Prothena Corporation PLC (NASDAQ:PRTA) will announce sales of $18.87 million for the current quarter, Zacks reports. Five analysts have provided estimates for Prothena Corporation PLC’s earnings, with estimates ranging from $500,000.00 to $30.33 million. Prothena Corporation PLC reported sales of $330,000.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 5,618.2%. The company is scheduled to report its next earnings report after the market closes on Tuesday, August 8th.

According to Zacks, analysts expect that Prothena Corporation PLC will report full-year sales of $18.87 million for the current fiscal year, with estimates ranging from $4.00 million to $31.20 million. For the next year, analysts anticipate that the firm will post sales of $43.97 million per share, with estimates ranging from $1.56 million to $101.20 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Prothena Corporation PLC.

Prothena Corporation PLC (NASDAQ:PRTA) last announced its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.99) EPS for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.33. Prothena Corporation PLC had a negative return on equity of 39.67% and a negative net margin of 16,012.49%. The business had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.26 million. During the same quarter in the prior year, the firm earned ($0.81) earnings per share. The business’s revenue was down 3.7% compared to the same quarter last year.

Several equities research analysts have recently commented on PRTA shares. Zacks Investment Research raised Prothena Corporation PLC from a “hold” rating to a “buy” rating and set a $59.00 price target on the stock in a research note on Tuesday, April 18th. BidaskClub raised Prothena Corporation PLC from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 19th. Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $70.00 price target on shares of Prothena Corporation PLC in a research note on Thursday, July 6th. ValuEngine raised Prothena Corporation PLC from a “sell” rating to a “hold” rating in a research note on Thursday, June 15th. Finally, BTIG Research assumed coverage on Prothena Corporation PLC in a research note on Friday, May 19th. They issued a “buy” rating and a $80.00 target price on the stock. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $76.45.

In other Prothena Corporation PLC news, insider Karin L. Walker sold 5,000 shares of the business’s stock in a transaction on Monday, July 17th. The stock was sold at an average price of $64.89, for a total value of $324,450.00. Following the completion of the transaction, the insider now directly owns 5,000 shares in the company, valued at approximately $324,450. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Dennis J. Selkoe sold 3,500 shares of the business’s stock in a transaction on Friday, July 7th. The shares were sold at an average price of $58.11, for a total value of $203,385.00. Following the completion of the transaction, the director now owns 6,345 shares of the company’s stock, valued at $368,707.95. The disclosure for this sale can be found here. 3.10% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of PRTA. BlackRock Inc. increased its position in shares of Prothena Corporation PLC by 95,458.7% in the first quarter. BlackRock Inc. now owns 2,733,934 shares of the biotechnology company’s stock valued at $152,526,000 after buying an additional 2,731,073 shares during the period. Woodford Investment Management Ltd increased its position in shares of Prothena Corporation PLC by 7.7% in the first quarter. Woodford Investment Management Ltd now owns 11,106,211 shares of the biotechnology company’s stock valued at $619,282,000 after buying an additional 795,700 shares during the period. FMR LLC increased its position in shares of Prothena Corporation PLC by 9.4% in the first quarter. FMR LLC now owns 5,659,308 shares of the biotechnology company’s stock valued at $315,733,000 after buying an additional 486,044 shares during the period. Norges Bank acquired a new position in shares of Prothena Corporation PLC during the fourth quarter valued at $18,277,000. Finally, Redmile Group LLC increased its position in shares of Prothena Corporation PLC by 29.9% in the first quarter. Redmile Group LLC now owns 849,483 shares of the biotechnology company’s stock valued at $47,393,000 after buying an additional 195,758 shares during the period.

ILLEGAL ACTIVITY NOTICE: “Analysts Expect Prothena Corporation PLC (NASDAQ:PRTA) Will Post Quarterly Sales of $18.87 Million” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/08/07/analysts-expect-prothena-corporation-plc-nasdaqprta-will-post-quarterly-sales-of-18-87-million.html.

About Prothena Corporation PLC

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Get a free copy of the Zacks research report on Prothena Corporation PLC (PRTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.